Company intelligence / Profile preview
EpimAb Biotherapeutics
Shanghai, Chinaepimab.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
EpimAb has multiple clinical-stage assets with promising results. EMB-06 (BCMA/CD3) showed positive Phase I results for multiple myeloma presented at ASH 2025. EMB-01 (EGFR/cMET) is in Phase I/II trials for GI cancers. The company has successfully licensed EMB-06 ex-China rights to Vignette Bio.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Bispecific antibodiesMultispecific antibodiesT cell engagers
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Vignette Bio (acquired by Candid Therapeutics)Medigene AG
Beyond the preview
Go deeper on EpimAb Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpimAb Biotherapeutics.